Clinical trials: Progressive Supranuclear Palsy (PSP)
Parkinson Disease, Progressive Supranuclear Palsy
Cholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL)
To perform a prospective cohort study with [(18)F]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features…
- Trial name
- NCT05459753
- Testing
- (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET, Dihydrotetrabenazine (DTBZ) PET
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Progressive Supranuclear Palsy, Corticobasal Degeneration
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
- Trial name
- NCT01174771
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Parkinson's Disease, Multiple System Atrophy
Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes
Parkinsonian syndrome is clinically characterized by the presence of resting tremor, rigidity, bradykinesia and postural instability.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, Vascular Parkinsonism
- Trial name
- PARKIMAGE (NCT02445469)
- Testing
- MRI exam of the brain
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease, Healthy Volunteers
Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), and healthy volunteers (HV).
- Conditions
- Alzheimer Disease, Healthy Volunteers, Progressive Supranuclear Palsy
- Trial name
- NCT03058965
- Testing
- [18F]MNI-958, [18F]Florbetapir, DaTscan
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer's Disease (AD), Parkinson's Disease (PD)
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
The goal of this study is to assess [18F]MNI-777 PET imaging as a tool to detect tau pathology in the brain of individuals who carry a clinical diagnosis of a tauopathy, including: Alzheimer's Disease (AD),Parkinson's disease…
- Conditions
- Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT02103894
- Testing
- [18F]T807 ([18F]MNI-777)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Healthy Volunteers, Alzheimer Disease
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
The overall goal of this protocol is to evaluate [18F]MNI-958 also known as APN-0000455 or PM-PBB3, a tau targeted radiopharmaceutical.
- Conditions
- Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
- Trial name
- NCT03545789
- Testing
- [18F]MNI-958
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Invicro
Progressive Supranuclear Palsy
Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy
The study will enroll 20 PSP and 8 normal subjects with complete neurological examination, 18F-PMPBB3 (APN-1607) PET and MRI assessment.
- Trial name
- NCT04541836
- Testing
- 18F-PMPBB3
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Parkinson Disease
Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear Palsy
The aim of this clinical trial is to explore the potential of novel 2nd generation tau PET radiotracers as biomarkers in cases suggestive of progressive supranuclear palsy (PSP), an atypical form of parkinsonism.
- Trial name
- Quanti-TAU-PET (NCT07105384)
- Testing
- Radiotracer
- Where
- Spain
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Progressive Supranuclear Palsy
Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease from the parkinsonian syndrome group. PSP is characterised by the association of a non-doparesponsive parkinsonian syndrome with axial signs.
- Trial name
- Qual-PSP (NCT03638505)
- Testing
- PSP-QoL
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis)
Biofluid Research on Age-Related or Inherited Neurodegeneration
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with…
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD)
- Trial name
- BRAIN (NCT07798700)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Progressive Supranuclear Palsy
Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)
The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).
- Trial name
- SCAN-PSP (NCT05579301)
- Where
- 2 sites in South Korea
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Progressive Supranuclear Palsy (PSP), Healthy Participants
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
This clinical study is being conducted to learn more about two new imaging drugs, called [18F]ABBV-964i and [18F]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive…
- Trial name
- NCT07348276
- Testing
- [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Invicro
Progressive Supranuclear Palsy
Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy
The main hypothesis is that the gait and postural deficits in the Caribbean form of PSP may be associated with a dysfunction of the cerebral cortex, as they result from sub-cortical involvement in classical forms.
- Trial name
- Gait-PSP (NCT04096651)
- Testing
- gait recordings, brain magnetic resonance imaging, oculomotor movement recordings
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Progressive Supranuclear Palsy (PSP), Cortico-Basal Degeneration (CBD) and Multiple System Atrophy (MSA) are degenerative brain conditions for which there are currently no curative treatments.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration, Multiple System Atrophy (MSA)
- Trial name
- PROSPECT-M (NCT02778607)
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University College, London
Parkinson Disease, Parkinsonism
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has.
- Conditions
- Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy
- Trial name
- NCT04518059
- Testing
- punch skin biopsy
- Where
- 2 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Parkinson Disease, Multiple System Atrophy
Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging
The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of…
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- NCT03872102
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Corticobasal Syndrome, Progressive Supranuclear Palsy
Diagnosing Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
- Conditions
- Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia
- Trial name
- NCT02964637
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Parkinson Disease, Progressive Supranuclear Palsy
Oxford Study of Quantification in Parkinsonism
The OxQUIP (Oxford QUantification In Parkinsonism) study is recruiting patients with Parkinson's Disease and Progressive Supranuclear Palsy.
- Trial name
- OxQUIP (NCT04139551)
- Where
- United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA)
UPenn Observational Research Repository on Neurodegenerative Disease
The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.
- Conditions
- Frontotemporal Degeneration(FTD), Primary Progressive Aphasia(PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Amyotrophic Lateral Sclerosis(ALS)
- Trial name
- UNICORN (NCT04715399)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Progressive Supranuclear Palsy, Healthy Volunteers
Evaluation of [18F]APN-1607 as a PET Biomarker
The overall goal of this protocol is to evaluate [18F]APN-1607 as a PET radiotracer for measuring longitudinal change in tau pathology in participants with PSP.
- Trial name
- NCT05005819
- Testing
- [18F] APN-1607
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Invicro